Abstract:Introduction Dilated cardiomyopathy (DCM) exhibits an annual incidence of 5-7 cases per 100,000 persons and a worldwide prevalence of 1:2500 individuals, with a genetic involvement in 35% of all cases (TTN and LMNA gene mutation accounting for the majority). Amongst the numerous genetic mutations, prior research has linked PTPN11 gene mutations to hypertrophic cardiomyopathy. Our case sheds light on the association between PTPN11 mutation and the development of isolated DCM. Case A 54-year-old lady with no remarkable medical history presented with typical symptoms of heart failure. CT coronary angiography revealed normal coronary arteries, and echocardiography (fig.1) demonstrated a left ventricular ejection fraction of 40%, with an indexed left ventricular end-diastolic volume (LVEDVi) of 79 ml/m2, suggestive of moderate-severe dilation. The patient also had a family history of non-ischemic heart failure with reduced ejection fraction (HFrEF) in her younger sister at the age of 45, reportedly due to stress but with no extensive workup. Stemming from the patient's refusal to undergo cardiac MRI, genetic testing was pursued, and she underwent whole genome testing which identified a missense mutation in coding exon 7 of the PTPN11 gene. Discussion PTPN11 is a gene that produces SHP2, a tyrosine phosphatase (PTP) protein. A gain of function mutation in PTPN11 is responsible for approximately 50% of cases of Noonan syndrome (NS). Although NS is commonly associated with hypertrophic cardiomyopathy (HCM) that leads to heart failure with preserved ejection fraction (HFpEF), the prevalence of HCM is low in individuals with NS caused by PTPN11 mutation. Conversely, DCM, which leads to HFrEF, has been rarely reported in NS, with only two documented cases in literature, albeit correlation with PTPN11 was not specified. Murine studies suggested that a deletion mutation in PTPN11 leads to abnormal activation of the Erk/MAPK protein and RhoA signaling pathways, resulting in rapid DCM development. Additionally, missense defects in PTPN11 were found to lead to prolonged phosphatase activity, mutations of which (mainly PP1 and PP2A, reportedly present in human hearts) also lead to DCM. Our patient was found to carry a specific PTPN11 mutation: c.794G>T(p.Arg265Leu), which is inherited in an autosomal dominant manner. Given that she had no predisposing factors for DCM, it is speculated that this PTPN11 variant may be an independent risk factor for isolated DCM induced HFrEF. Further clinical correlation and familial testing are required to fully understand the effect of this variant on the heart, which could have significant implications for both diagnosis and treatment of this debilitating cardiovascular disorder.

Genetic variations in PTPN11 lead to a recurrent Left Ventricular Outflow Tract Obstruction phenotype in childhood hypertrophic cardiomyopathy

Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy: Acute Results and Three-Year Noninvasive Follow-Up in 18 Patients.

Clinical and mutation profile of pediatric patients with RASopathy-associated hypertrophic cardiomyopathy: results from a Chinese cohort

PTPN11 Gene Mutations and Its Association with the Risk of Congenital Heart Disease

Evaluation of potential links between phenotypic features and genetic variants in left ventricular outflow tract obstruction in hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging

PTPN11 Mutation, A Heartbreaking Revelation

Identification of Rare Variants in Right Ventricular Outflow Tract Obstruction Congenital Heart Disease by Whole-Exome Sequencing

Clinical Outcomes and Genetic Analyses of Restrictive Cardiomyopathy in Children.

Left Bundle Pacing for Left Bundle Branch Block and Intermittent Third-Degree Atrioventricular Block in a MYH7 Mutation-Related Hypertrophic Cardiomyopathy with Restrictive Phenotype in a Child.

Whole exome sequencing reveals genetic landscape associated with left ventricular outflow tract obstruction in Chinese Han population

The Cumulative Effects of the MYH7-V878A and CACNA1C-A1594V Mutations in a Chinese Family with Hypertrophic Cardiomyopathy

A Novel Mutation in the Tropomyosin 1 Gene in a Chinese Patient with Hypertrophic Cardiomyopathy

Novel association of LBX1 mutation with tetralogy of Fallot and hypertrophic cardiomyopathy: implications for cardiac development

The clinical features, outcomes and genetic characteristics of hypertrophic cardiomyopathy patients with severe right ventricular hypertrophy

Genetic basis of hypertrophic cardiomyopathy in children

HAND1 Loss-of-Function Mutation Causes Tetralogy of Fallot.

Genophenotypic correlates and long-term outcome prognosticators of left ventricular non-compaction in children

[Mutation and Clinical Relevance in a Large Cohort of Unrelated Chinese Patients with Hypertrophic Cardiomyopathy].

Hypertrophic cardiomyopathy with latent obstruction: Clinical characteristics and surgical results

Arrhythmias May Hide a Genetic Cardiomyopathy in Left Ventricular Hypertrabeculation in Children: A Single-Center Experience

Association between Genotype, Presentation, and Outcome in Childhood Idiopathic and Hereditary Pulmonary Arterial Hypertension